

Home Contact Us Site Map

August 7. 2002

Search



About Collagenex Our Products Investor Relations Core Technologies

Annual Reports | Stock Quote | Stock Chart | Press Releases | SEC Filings | Conference Calls | E-mail Alerts |





Investor Relations

Press Releases

CollaGenex Pharmaceuticals, Inc. (ticker: CGPI, exchange: NASDAQ) News Release - 7/2/2001

CollaGenex Pharmaceuticals Introduces Periostat Tablet; Tablets Offe Significant Manufacturing Efficiencies and Patient Benefits Compared Current Capsule Formulation

NEWTOWN, Pa., Jul 2, 2001 (BUSINESS WIRE) -- CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced the launch of a tab formulation of Periostat(R), the Company's lead drug for the adjunctive treatment of adult periodontitis.

The tablets will eventually replace the current capsule formulation of Periostat and offer significant manufacturing efficiencies and patient benef

"We are pleased to be introducing our tablet formulation of Periostat ahea of schedule," said Brian M. Gallagher, PhD, chairman, president and chief executive officer of CollaGenex. "Many patients find tablets easier to swall than capsules, and tablets are a much preferred dosage formulation in Europe, where we hope to begin receiving the necessary regulatory approvals for marketing later this year."

"The newly-developed manufacturing method for tablets allows our contra manufacturer to produce substantially larger batch sizes than previously," continued Dr. Gallagher, "which leads to considerable improvements in manufacturing efficiency. We expect to see the full financial impact of this the fourth quarter of this year."


One additional benefit of the tablet formulation is that the CollaGenex salesforce will now be able to sample a convenient blister pack to dentists facilitate trial of Periostat in their patients. Previously, sampling had been limited to the provision of a bottle of 100 capsules, from which the dentist had to dispense samples for patients.

In line with its stated goal to outsource capital-intensive operations such a manufacturing and packaging, CollaGenex has contracted with PMRS Inc., Horsham, PA, to manufacture Periostat tablets for worldwide supply, and P Inc., Philadelphia, PA to pack product for the US market.

CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on providing innovative medical therapies to the dental market.

The Company's lead product, Periostat, was approved by the FDA in September 1998 and is the first and only pharmaceutical to treat periodon





disease by inhibiting the enzymes that destroy periodontal support tissues

In February 2001, the FDA granted marketing approval for a new tablet formulation for Periostat. Periostat is marketed to the dental community b CollaGenex through a professional pharmaceutical sales force composed o approximately 120 sales representatives and managers.

Currently, the Company's dental sales force is also marketing Vioxx(R), a Merck & Co. drug that CollaGenex co-promotes for the treatment of acute dental pain, and Dentaplex(TM), a unique formulation of vitamins and mineral supplements developed by CollaGenex and MediNiche, Inc. to promote oral health.

Research has shown that the enzyme suppression technology underlying Periostat may also be applicable to other diseases involving destruction of the body's connective tissues, including cancer metastases (Metastat) and broad range of inflammatory diseases.

CollaGenex is developing a series of novel, proprietary compounds known IMPACS (Inhibitors of Multiple Proteases and Cytokines) to address these applications. The Company intends to pursue further research and development of these technologies primarily through partnerships with thi parties.

To receive additional information on the Company, please visit our Web si at www.collagenex.com, which is not a part of this press release.

Periostat(R), Metastat(R), IMPACS(R) and Dentaplex(TM) are trademarks o CollaGenex Pharmaceuticals, Inc. CollaGenex(R) and Periostat(R) are trademarks of CollaGenex International Limited VIOXX(R) is a trademark o Merck & Co., Inc.

CONTACT:

CollaGenex Pharmaceuticals, Inc. Nancy C. Broadbent, 215/579-7388

or

Investor Relations:

In-Site Communications, Inc. Lisa Carlton-Wilson, 212/759-3929

back to top

Home / Contact Us / Site Map / Press Releases / About CollaGenex / Our Products
Investor Relations / Core Technologies / Resources